This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to also cap their asthma chronic obstructive pulmonary disease drugs at $35.
GSK is the latest company to cap out-of-pocket costs at $35 monthly. for its asthma and chronic obstructive pulmonary disease (COPD) medicines. This program will be implemented no later than Jan. 1, 2025, the company said in the press release.
The medications included are:
GSK also recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%.
Related: AstraZeneca to Cap Asthma and COPD Meds at $35 a Month
Related: Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to cap their respiratory medications at $35.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More